Moleculin Biotech Selects PCG Advisory Group for Integrated Strategic Communications
HOUSTON, TX and NEW YORK, NY -- (Marketwired) -- 06/28/16 -- Moleculin Biotech, Inc., (NASDAQ: MBRX) , today announced the Company has retained PCG Advisory Group, a leading investor relations and integrated communication firm, to serve as an advisor for investor relations, social and digital media and public relations.
Walter Klemp, Chairman and CEO of Moleculin, stated, "After learning about all of PCG's offerings, we were convinced their vision for Moleculin is in complete agreement with the vision of our management team."
Jeff Ramson, Founder and CEO of PCG Advisory Group said, "PCG is excited to work with Moleculin. Moleculin is a first class pharmaceutical company with great science and a great story to share. At PCG we uphold Moleculin as a Company which understands and embraces the disciplined use of social media to build dynamic social audiences. Moleculin represents the perfect partner to develop highly engaged communities of stakeholders. We look forward to working together for the long term."
About Moleculin Biotech, Inc.:
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system. The other portfolio targets the metabolism of tumors.
About PCG Advisory Group:
Founded in 2008 and headquartered in New York City, PCG Advisory Group is dedicated to the delivery of top tier investor relations, strategic advisory, communications, and innovative digital media services for the micro and small cap public company marketplace. PCG has extensive experience with life sciences, technology, energy and other emerging growth companies, both in the US and internationally.
PCG's team of senior level professionals bring many years of direct advisory experience, along with unique and high quality relationships amongst the investment and media communities. Our primary focus is building a shareholder base and expanding market awareness through very professional methods and initiatives.
PCG's Capital Markets Advisory Services include overall investor marketing and communications strategy development to increase and leverage awareness, visibility and credibility. PCG's Social and Digital Media services include maximizing social and professional digital media channels to effectively and accurately communicate clients' specific opportunities.
Please follow us on our social media channels:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events, future expectations, plans and prospects. Although Moleculin Biotech believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under the heading "Risk Factors" in our Registration Statement on Form S-1 originally filed with the Securities and Exchange Commission on February 1, 2016, as amended (Registration No. 333-209323). Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Moleculin Biotech Inc.
Kirin M. Smith
Chief Operating Officer
Chief Communications Officer
Source: Moleculin Biotech, Inc.
Released June 28, 2016